Liraglutide and Heart Failure in Type 2 Diabetes

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2014 by Karolinska Institutet
Sponsor:
Collaborator:
Örebro University, Sweden
Information provided by (Responsible Party):
Thomas Nystrom, Karolinska Institutet
ClinicalTrials.gov Identifier:
NCT01425580
First received: August 26, 2011
Last updated: April 6, 2014
Last verified: April 2014
  Purpose

Glucagon-like peptide-1 (GLP-1) is a naturally occurring incretin with insulinotropic properties. Apart from the glycemic actions, cardiovascular effects by GLP-1 have recently been reviewed. Receptors for GLP-1 are expressed in the rodent and human heart and acute activation of GLP-1 signalling has been shown to influence e.g. heart rate and blood pressure. In a knock-out mouse model, GLP-1R-/- mice exhibited a defective cardiovascular contractile response together with left ventricular hypertrophy. GLP-1 improves severe left ventricular heart failure in humans suffering from a myocardial infarction. Hence, it has been demonstrated that GLP-1 exerts direct functional effects through both GLP-1 receptor dependent and independent pathways in the heart.

Native GLP-1 is an extremely short acting peptide, with a half-time breakdown of 1-2 minutes, a feature that makes it unsuitable as a drug treatment for type 2 diabetes. To this end, several long-acting GLP-1 analogues, drugs for treating type 2 diabetes, have been tested for this purpose. The analogue liraglutide exerts its effects via the native GLP-1 receptor, localized not only on the pancreatic β-cells, but also in the human heart. Interestingly, liraglutide has been demonstrated to have beneficial effect on heart function in mice. Taken together, recent data shows that GLP-1 and its stable analogue liraglutide exert beneficial cardiovascular effects.

The purpose of this study is to determine whether the glucagon-like peptide-1 (GLP-1) analogue liraglutide improves heart function (measured as left ventricle longitudinal function and/or functional reserve during rest and/or after exercise) after 18 weeks of liraglutide + metformin, compared with glimepiride + metformin, using tissue Doppler echocardiography.


Condition Intervention Phase
Congestive Heart Failure
Type 2 Diabetes Mellitus
Drug: liraglutide
Drug: glimepiride
Drug: Metformin
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment Versus Glimepiride Both in Combination With Metformin

Resource links provided by NLM:


Further study details as provided by Karolinska Institutet:

Primary Outcome Measures:
  • Left ventricle longitudinal function and/or functional reserve during rest and/or after exercise using tissue Doppler echocardiography [ Time Frame: 18 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • 24-hour blood pressure [ Time Frame: 18 weeks ] [ Designated as safety issue: No ]
  • Energy delivering from the carotid artery [ Time Frame: 18 weeks ] [ Designated as safety issue: No ]
  • N-terminal pro b-type natriuretic peptide (NT-proBNP) levels in serum over time and symptoms of dyspnea or fatigue as assessed by patient and clinician using established scoring systems [ Time Frame: 18 weeks ] [ Designated as safety issue: No ]
  • Gene and protein expression (Affymetrix/proteomics) [ Time Frame: 18 weeks ] [ Designated as safety issue: No ]
  • Plasma markers of inflammation i.e. hsCRP, IL-6, TNF-α and PAI-1 [ Time Frame: 18 weeks ] [ Designated as safety issue: No ]
  • Plasma markers of endothelial activation i.e. E-selectin, VCAM-1, ICAM-1 and plasma levels of nitrate/nitrite [ Time Frame: 18 weeks ] [ Designated as safety issue: No ]
  • Lipids [ Time Frame: 18 weeks ] [ Designated as safety issue: No ]
  • A1c [ Time Frame: 18 week ] [ Designated as safety issue: No ]
  • Body weight [ Time Frame: 18 weeks ] [ Designated as safety issue: No ]
  • Adverse events in terms of hypoglycaemia [ Time Frame: 18 weeks ] [ Designated as safety issue: Yes ]
  • Quality of life (SF 36) [ Time Frame: 18 weeks ] [ Designated as safety issue: No ]
  • Exercise ECG, including working capacity [ Time Frame: 18 weeks ] [ Designated as safety issue: No ]
  • Global LV function (echocardiography) expressed as ejection fraction (EF) [ Time Frame: 18 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 80
Study Start Date: January 2012
Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: liraglutide
The present trial is a two centre, open, assessor-blinded and active-controlled, parallel-group trial, in combination with metformin. The trial will compare the treatment with liraglutide 1.8 mg (s.c) QD + metformin up to 1 g BID, with that of glimepiride 4 mg QD (comparator) + metformin up to 1 g BID, on LV function in subjects with type 2 diabetes.
Drug: liraglutide
1.8 mg s.c. (QD)
Drug: glimepiride
4 mg p.o. (QD)
Drug: Metformin
500 mg p.o. (BID)
Active Comparator: glimepiride
4 mg p.o. (QD)
Drug: liraglutide
1.8 mg s.c. (QD)
Drug: glimepiride
4 mg p.o. (QD)
Drug: Metformin
500 mg p.o. (BID)

Detailed Description:

The subjects will attend a screening visit (Visit 1) in order to assess their eligibility. If found eligible, the subjects will return at Visit 2 within approximately 4 weeks, after Visit 1, with an up-titration with metformin 1 g BID or the maximal tolerated dosage of metformin (Run-in period).

At Visit 2 patients will be tested for;

  • Heart function at rest and during an exercise ECG Stress Test with tissue Doppler echocardiography
  • 24-hour blood pressure
  • Anthropometric assessment
  • Symptoms of dyspnea or fatigue (scoring system, classified as NYHA).
  • Quality of life (SF 36)
  • Blood test (venipuncture)

Subsequently thereafter, subjects will during visit 2 be randomized to receive either liraglutide 1.8 mg s.c. (initial dose of 0.6 mg with an up-titration of 0.6 mg every week, final dose 1.8 mg QD) or glimepiride 4 mg p.o (initial dose of 2 mg, with an up-titration of 1 mg every week, final dose 4 mg QD).

At Visit 2, subjects will be supplied with a glucose meter (Abbot Contour) and instruction on use of the device including regular calibration according to the manufacturer's instruction. Subjects will be instructed on how to record the results of the self measured plasma glucose (SMPG) values in the meter. Subjects will then ask to monitor a 7 point profile glucose curve consecutively in three days before visit 3, at visit 4 and at the end of treatment (visit 5). SMBG values will be transferred via a computerized system (Diasend®).

Visit 3. Telephone visit. Self-reporting glucose measurements.

Visit 4. Telephone visit. Self-reporting glucose measurements.

At week 18 (Visit 5), subjects will be re-tested for:

  • Heart function at rest and during an exercise ECG Stress Test with tissue Doppler echocardiography
  • 24-hour blood pressure
  • Anthropometric assessment
  • Symptoms of dyspnea or fatigue (scoring system, classified as NYHA).
  • Quality of life (SF 36)
  • Blood test (venipuncture)
  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Type 2 diabetes.
  2. Heart Failure, visualized with echocardiography, one of the following (2.1, 2.2 or 2.3).

    • Ejection Fraction ≤ 50%.
    • Decreased systolic velocity (four chamber view) where two, out of four segments (Septum, Lateral, Inferior and Anterior Wall) has a relative decrease in velocity of 20% compared to a normal population.
    • Evidence of diastolic dysfunction as shown by abnormal left ventricular relaxation, filling, diastolic distensibility or stiffness. An E/E' ratio (ratio of early diastolic velocities of mitral inflow derived Doppler imaging and myocardial movement derived by tissue Doppler imaging) >15 is considered diagnostic of diastolic dysfunction and an E/E' ratio < 8 as diagnostic of the absence of diastolic heart failure. An increased left atrial size (>49 ml/ m2) and an increased left ventricular mass (>122 g/m2 in women and >149 g/m2 in men) are considered sufficient evidence of diastolic dysfunction when the E/E' ratio is inconclusive.
  3. HbA1c (accordingly to IFCC) 60 mmol/mol - 95 mmol/mol.
  4. If antihypertensive treatment, the medication has to be stable, no change, for the last 1 month.
  5. Male and female subjects, 18-70 years of age.
  6. Signed informed consent form.

Exclusion Criteria:

  1. Type 1 diabetes (autoantibody positive).
  2. Any history of receiving GLP-1 analogues or dipeptidyl peptidase inhibitors (DPP-IV inhibitor) or glimeperide.
  3. Previous treatment with glitazones within 6 months.
  4. Previous treatment with other sulphonylurea within 3 months.
  5. Previous treatment with insulin (any regimen) within 1 month.
  6. Known severe heart failure, classified as NYHA 3-4.
  7. Significant ischemic heart disease (defined as angina-limited exercise or unstable angina); documented acute myocardial infarction (MI) within the previous 8 weeks.
  8. Active myocarditis; malfunctioning artificial heart valve.
  9. Atria fibrillation or flutter
  10. History of ventricular tachycardia within 3 months before study entry; second- or third-degree atrioventricular block.
  11. Implanted pacemaker.
  12. Supine systolic blood pressure <85 mm Hg or >200 mm Hg.
  13. Primary renal impairment (creatinine clearance < 30 ml/min), or creatinine clearance < 60 ml/min if treated with metformin.
  14. Uncorrected hypokalemia or hyperkalemia (potassium <3.5 mmol/l or >5.5 mmol/l).
  15. Significant anemia (Hb < 90 g/l)
  16. Treatment with another investigational agent within 30 days before study entry, judged by the investigator.
  17. Severe gastrointestinal disease, including gastroparesis. As judged by the investigator.
  18. Body mass index (BMI) > 40 kg/m2.
  19. Malignant neoplasm requiring chemotherapy, surgery, radiation or palliative therapy in the previous 5 years. Patients with intraepithelial squamous cell carcinoma of the skin treated with topical 5FU and subjects with basal cell skin cancer are allowed to enter the trial.
  20. Females of child bearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (adequate contraceptive measures as required by local law or practice).
  21. Current drug and alcohol abuse.
  22. History of acute or chronic pancreatitis
  23. Subjects considered by the investigator to be unsuitable for the study.

    -

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01425580

Contacts
Contact: Thomas Nyström, MD, PhD +4686163211 thomas.nystrom@sodersjukhuset.se
Contact: Johan Jendle, MD, PHD johan.jendle@liv.se

Locations
Sweden
Karolinska Institutet, Division of Internal Medicine Södersjukhuset AB Recruiting
Stockholm, Sweden, 118 83
Contact: Thomas Nyström, MD    +4686163211    thomas.nyström@sodersjukhuset.se   
Contact: Johan Jendle, MD       johan.jendle@liv.se   
Principal Investigator: Thomas Nyström, MD         
Principal Investigator: Johan Jendle, MD         
Karolinska Institutet, Department of Clinical Science and Education, Södersjukhuset Recruiting
Stockholm, Sweden, 118 83
Contact: Thomas Nyström, MD, PhD    +4686163211    thomas.nystrom@sodersjukhuset.se   
Principal Investigator: Johan Jendle, MD, PhD         
Sponsors and Collaborators
Thomas Nystrom
Örebro University, Sweden
Investigators
Principal Investigator: Johan Jendle, MD, PhD University of Örebro
  More Information

No publications provided

Responsible Party: Thomas Nystrom, MD, PhD, Karolinska Institutet
ClinicalTrials.gov Identifier: NCT01425580     History of Changes
Other Study ID Numbers: EU-nr 2010-022695-31, 2010-022695-31
Study First Received: August 26, 2011
Last Updated: April 6, 2014
Health Authority: Sweden: Medical Products Agency

Keywords provided by Karolinska Institutet:
Congestive Heart Failure
Type 2 Diabetes Mellitus
GLP-1
Liraglutide

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Heart Failure
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Heart Diseases
Cardiovascular Diseases
Glimepiride
Liraglutide
Metformin
Glucagon-Like Peptide 1
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Arrhythmia Agents
Cardiovascular Agents
Therapeutic Uses
Immunosuppressive Agents
Immunologic Factors
Incretins
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists

ClinicalTrials.gov processed this record on August 28, 2014